Arcadia Biosciences, Inc.RKDAEarnings & Financial Report
Arcadia Biosciences is a publicly traded American agricultural biotechnology headquartered in Davis, California focused on the development of traits to enhance crop quality and productivity. The company is partly owned by Moral Compass Corporation.
RKDA Q4 FY2025 Key Financial Metrics
Revenue
$901.0K
Gross Profit
$193.0K
Operating Profit
$-1.4M
Net Profit
$-1.3M
Gross Margin
21.4%
Operating Margin
-152.8%
Net Margin
-148.3%
YoY Growth
-25.8%
EPS
$-0.97
Arcadia Biosciences, Inc. Q4 FY2025 Financial Summary
Arcadia Biosciences, Inc. reported revenue of $901.0K (down 25.8% YoY) for Q4 FY2025, with a net profit of $-1.3M (up 67.1% YoY) (-148.3% margin). Cost of goods sold was $708.0K, operating expenses totaled $1.6M.
Key Financial Metrics
| Total Revenue | $901.0K |
|---|---|
| Net Profit | $-1.3M |
| Gross Margin | 21.4% |
| Operating Margin | -152.8% |
| Report Period | Q4 FY2025 |
Arcadia Biosciences, Inc. Annual Revenue by Year
Arcadia Biosciences, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.9M).
Arcadia Biosciences, Inc. Quarterly Revenue & Net Profit History
Arcadia Biosciences, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $901.0K | -25.8% | $-1.3M | -148.3% |
| Q3 FY2025 | $1.3M | -15.3% | $856.0K | 65.7% |
| Q2 FY2025 | $1.5M | +11.4% | $-4.5M | -306.4% |
| Q1 FY2025 | $1.2M | +21.6% | $2.6M | 216.6% |
| Q4 FY2024 | $1.2M | +93.8% | $-4.1M | -334.5% |
| Q3 FY2024 | $1.5M | +18.4% | $-1.6M | -104.9% |
| Q2 FY2024 | $1.3M | +0.7% | $1.1M | 81.2% |
| Q1 FY2024 | $987.0K | -19.9% | $-2.4M | -245.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $987000 | $1.3M | $1.5M | $1.2M | $1.2M | $1.5M | $1.3M | $901000 |
| YoY Growth | -19.9% | 0.7% | 18.4% | 93.8% | 21.6% | 11.4% | -15.3% | -25.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $16.0M | $17.4M | $15.2M | $13.5M | $13.0M | $7.8M | $8.6M | $6.5M |
| Liabilities | $5.6M | $5.8M | $5.1M | $7.3M | $4.1M | $3.3M | $3.1M | $2.4M |
| Equity | $10.6M | $11.7M | $10.3M | $6.2M | $8.9M | $4.5M | $5.4M | $4.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.2M | $-2.5M | $-1.8M | $-2.2M | $-1.6M | $-2.0M | $-257000 | $-861000 |